Effects of Glucose Fluctuation Targeted Intervention on the Prognosis of Patients with Type 2 Diabetes following the First Episode of Cerebral Infarction

Qingqing Lou, Xiaodan Yuan, Shujie Hao, Joshua D Miller, Juan Yan, Panpan Zuo, Jianing Li, Lihong Yang, Hong Li, Qingqing Lou, Xiaodan Yuan, Shujie Hao, Joshua D Miller, Juan Yan, Panpan Zuo, Jianing Li, Lihong Yang, Hong Li

Abstract

Objective: The purpose of this study was to assess the effects of glucose fluctuation targeted intervention on neurologic function, independent living skills, and quality of life in type 2 diabetes patients following the first episode of cerebral infarction (CI).

Methods: This was a randomized control trial. Following confirmed cerebral infarction, 75 patients with type 2 diabetes were randomized into 2 groups: control group (n = 37) with usual care, focused on hemoglobin A1c (HbA1c) control, targeting A1c < 7%, and intervention group (n = 37) with usual care, focused on hemoglobin A1c (HbA1c) control, targeting A1c < 7%, and intervention group (.

Results: After 6 months, data from 63 patients were analyzed (30 in the control group, 33 in the intervention group). There was no difference (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (P > 0.05) in the reduction of A1c between the 2 groups, but the reductions of LAGE (.

Conclusion: Glucose fluctuation targeted intervention can improve nerve function for patients with T2DM following the first CI episode. This trial is registered with NCT03932084.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Copyright © 2020 Qingqing Lou et al.

Figures

Figure 1
Figure 1
Flow diagram of study enrollment.
Figure 2
Figure 2
Flow diagram for two groups.
Figure 3
Figure 3
Changes in 2hPG from baseline to 6 months between the control and glucose fluctuation target management groups.
Figure 4
Figure 4
Changes in LAGE from baseline to 6 months between the control and glucose fluctuation target management groups.
Figure 5
Figure 5
Changes in 1,5-AG from baseline to 6 months between the control and glucose fluctuation target management groups.

References

    1. Goldstein L. B., Bushnell C. D., Adams R. J., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517–584. doi: 10.1161/STR.0b013e3181fcb238.
    1. Kiers L., Davis S. M., Larkins R., et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(4):263–270. doi: 10.1136/jnnp.55.4.263.
    1. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. doi: 10.2337/diab.44.8.968.
    1. Nathan D. M., Buse J. B., Davidson M. B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–1972. doi: 10.2337/dc06-9912.
    1. Temelkova-Kurktschiev T. S., Koehler C., Henkel E., Leonhardt W., Fuecker K., Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23(12):1830–1834. doi: 10.2337/diacare.23.12.1830.
    1. Kohnert K. D., Heinke P., Vogt L., Salzsieder E. Utility of different glycemic control metrics for optimizing management of diabetes. World Journal of Diabetes. 2015;6(1):17–29. doi: 10.4239/wjd.v6.i1.17.
    1. Suh S., Kim J. H. Glycemic variability: how do we measure it and why is it important? Diabetes and Metabolism Journal. 2015;39(4):273–282. doi: 10.4093/dmj.2015.39.4.273.
    1. Kuroda M., Shinke T., Sakaguchi K., et al. Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography. Cardiovascular Diabetology. 2015;14:p. 78. doi: 10.1186/s12933-015-0236-x.
    1. Jiao X. M., Zhang X. G., Xu X. U., et al. Blood glucose fluctuation aggravates lower extremity vascular disease in type 2 diabetes. European Review for Medical and Pharmacological Sciences. 2014;18(14):2025–2030. doi: 10.4314/tjpr.v13i7.24.
    1. Ito T., Ichihashi T., Fujita H., et al. The impact of intraday glucose variability on coronary artery spasm in patients with dysglycemia. Heart and Vessels. 2019;34(8):1250–1257. doi: 10.1007/s00380-019-01353-w.
    1. Muggeo M., Zoppini G., Bonora E., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona diabetes study. Diabetes Care. 2000;23(1):45–50. doi: 10.2337/diacare.23.1.45.
    1. Hsu C. W. Glycemic control in critically ill patients. World Journal of Critical Care Medicine. 2012;1(1):31–39. doi: 10.5492/wjccm.v1.i1.31.
    1. Benalia M., Zeller M., Mouhat B., et al. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction. Diabetes & Metabolism. 2019;45(5):446–452. doi: 10.1016/j.diabet.2019.01.012.
    1. Wu C. H., Liu B. The Fourth National Cerebrovascular Disease Conference. Vol. 6. China Medical News; 1996.
    1. Colman P. G., Thomas D. W., Zimmet P. Z., Welborn T. A., Garcia-Webb P., Moore M. P. New classification and criteria for diagnosis of diabetes mellitus. The Australasian Working Party on Diagnostic Criteria for Diabetes Mellitus. The New Zealand Medical Journal. 1999;112(1086):139–141.
    1. Brott T., Adams HP Jr, Olinger C. P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864–870. doi: 10.1161/01.STR.20.7.864.
    1. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scottish Medical Journal. 1957;2(5):200–215. doi: 10.1177/003693305700200504.
    1. Sulter G., Steen C., De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 1999;30(8):1538–1541. doi: 10.1161/01.STR.30.8.1538.
    1. Banks J. L., Marotta C. A. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38(3):1091–1096. doi: 10.1161/01.STR.0000258355.23810.c6.
    1. de Haan R., Limburg M., Bossuyt P., van der Meulen J., Aaronson N. The clinical meaning of Rankin ‘handicap’ grades after stroke. Stroke. 1995;26(11):2027–2030. doi: 10.1161/01.STR.26.11.2027.
    1. Kwon S., Hartzema A. G., Duncan P. W., Min-Lai S. Disability measures in stroke relationship among the Barthel index, the functional independence measure, and the modified Rankin scale. Stroke. 2004;35(4):918–923. doi: 10.1161/01.STR.0000119385.56094.32.
    1. Duncan P. W., Wallace D., Lai S. M., Johnson D., Embretson S., Laster L. J. The stroke impact scale version 2.0: evaluation of reliability, validity, and sensitivity to change. Stroke. 1999;30(10):2131–2140. doi: 10.1161/01.str.30.10.2131.
    1. Lan Y., Huang D. F., Hu X. Q., Xu G. Q., Li K. Reliability of the Chinese Version of stroke Impact Scale. Chinese Journal of Clinical Rehabilitation. 2004;8(28):6009–6011.
    1. Koga M., Murai J., Saito H., et al. Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. Clinical Biochemistry. 2010;43(15):1265–1267. doi: 10.1016/j.clinbiochem.2010.08.001.
    1. Dworacka M., Winiarska H., Borowska M., Abramczyk M., Bobkiewicz-Kozlowska T., Dworacki G. Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circulation Journal. 2007;71(6):962–967. doi: 10.1253/circj.71.962.
    1. Watanabe M., Kokubo Y., Higashiyama A., Ono Y., Miyamoto Y., Okamura T. Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis. 2011;216(2):477–483. doi: 10.1016/j.atherosclerosis.2011.02.033.
    1. Ikeda N., Hara H., Hiroi Y., Nakamura M. Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. Atherosclerosis. 2016;253:1–6. doi: 10.1016/j.atherosclerosis.2016.08.016.
    1. Lachin J. M., Genuth S., Nathan D. M., Zinman B., Rutledge B. N., for the DCCT/EDIC Research Group Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes. 2008;57(4):995–1001. doi: 10.2337/db07-1618.
    1. Yoon J. E., Sunwoo J. S., Kim J. S., et al. Poststroke glycemic variability increased recurrent cardiovascular events in diabetic patients. Journal of Diabetes and its Complications. 2017;31(2):390–394. doi: 10.1016/j.jdiacomp.2016.11.014.
    1. Ma G., Xu J. H. Effects of blood glucose management on rehabilitation after ischemic stroke in patients with type 2 diabetes mellitus. Modern Diagnosis and Treatment. 2013;24(16):3752–3753.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する